Patients with relapsing–remitting multiple sclerosis have been shown to benefit from disease-modifying treatments over prolonged periods. More focus should now be placed on monitoring the long-term evolution of this disease (making use of tools such as MRI), alongside the patients' response and adherence to such treatments.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Doggrell, S. A. Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin. Pharmacother. 11, 1225–1230 (2010).
Katrych, O., Simone, T. M., Azad, S. & Mousa, S. A. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol. Disord. Drug Targets 8, 512–519 (2009).
Ford, C. et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler. 16, 342–350 (2010).
Brown, M. G. et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69, 1498–1507 (2007).
Trojano, M. et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol. 61, 300–306 (2007).
Cutter, G. R. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871–882 (1999).
Barkhof, F., Calabresi, P. A., Miller, D. H. & Reingold, S. C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256–266 (2009).
Fisniku, L. K. et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 64, 247–254 (2008).
Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann. Neurol. 65, 268–275 (2009).
Rovaris, M. et al. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 72, 1693–1701 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Filippi has acted as a consultant and received honoraria and research support from Bayer Schering Pharma, Biogen-Dompé, Genmab A/S, Merck Serono and Teva Pharmaceutical Industries.
M. A. Rocca has acted as a consultant for Bayer Schering Pharma and received honoraria from Biogen-Dompé.
Rights and permissions
About this article
Cite this article
Filippi, M., Rocca, M. Monitoring long-term treatments in multiple sclerosis. Nat Rev Neurol 6, 421–422 (2010). https://doi.org/10.1038/nrneurol.2010.88
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.88
This article is cited by
-
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients
Journal of Neurology (2022)
-
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
BMC Neurology (2013)
